Influx Healthtech Limited IPO Details
| Detail | Description |
|---|---|
| IPO Date | June 18, 2025 to June 20, 2025 |
| Listing Date | - |
| Face Value | ₹ 10 per share |
| Issue Price Band | ₹ 91 to ₹ 96 per share |
| Lot Size | 1,200 Shares |
| Total Issue Size (Ex Market Maker) | 57,94,800 shares (aggregating up to ₹ 55.63 Cr) |
| Fresh Issue (Ex Market Maker) | 46,94,400 shares (aggregating up to ₹ 45.07 Cr) |
| Offer for Sale (Ex Market Maker) | 11,00,400 shares of ₹10 (aggregating up to ₹ 10.56 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,81,50,000 shares |
| Share Holding Post Issue | 2,31,50,400 shares |
| Market Maker Portion | 3,06,000 shares |
About Influx Healthtech Limited IPO
Influx Healthtech Limited, a CDMO based in Mumbai is launching its Initial Public Offering (IPO) to raise around ₹55.63 crore. The IPO includes a fresh issue of 46.94 lakh shares worth about ₹45.07 crore and an offer-for-sale (OFS) of 11 lakh shares valued at roughly ₹10.56 crore. Shares are priced between ₹91 and ₹96 each. Subscriptions will be taken from June 18 to June 20, 2025; the smallest lot is 1,200 shares. Traders can expect the stock to debut on the NSE SME platform on June 25, 2025.
Company Background
Influx Healthtech Limited has been operating as a CDMO in the health and wellness sector since its incorporation in September 2020. The company specializes in contract manufacturing, providing product development and manufacturing services for nutraceuticals, cosmetics, ayurvedic products and veterinary feed supplements. Its client base includes notable brands such as Bling Brands, Pursuit of Wellness, Aarkios Health, HSHS Nutraceuticals Limited, Novus Life Science, Bruder Life Science, Fredun Pharmaceuticals and BigFlex Lifescience.
Operations & Product Range
Facility & Production:
Influx Healthtech operates three manufacturing facilities in Thane, Maharashtra, within an area of 9,676 sq. ft., 13,000 sq. ft. and 14,000 sq. ft respectively. These facilities are equipped to manufacture a wide variety of products, including tablets, capsules, softgels, jellies, oral dissolving films (ODFs), effervescent tablets, cosmetics, herbal formulations, veterinary and homecare products.
Brands & Market Presence:
The company supports nutraceutical and cosmetic firms by providing end-to-end services, from product development to regulatory support. Its strong CDMO capabilities have established Influx Healthtech as a trusted partner for several leading brands in the wellness and pharma sectors.
Revenue Channels
Influx Healthtech generates revenue primarily through:
- Contract manufacturing for third-party brands in nutraceuticals, cosmetics, ayurvedic and veterinary segments.
- Product development and regulatory support services for client brands.
- The company reported a revenue of ₹104.99 crore and a net profit of ₹13.37 crore for FY25, showing consistent growth in both revenue and profitability.
Management & Shareholding
Promoters & Shareholding:
Mr. Munir Abdul Ganee Chandniwala, Mrs. Shirin Munir Ahmed Chandniwala and Mr. Abdul Ganee Abdul Rasul Chandniwala are included in the promoters of the company. Promoters hold 99.85% shares before the IPO but after the IPO, it will decrease to 73.53%.
Details of the promoters and their shareholding percentages are not explicitly listed in the available sources. However, the company is led by experienced professionals in the healthcare manufacturing sector and the IPO includes both a fresh issue and an offer-for-sale by existing shareholders.
Board Members:
The company is led by experienced professionals in the healthcare manufacturing sector on its board. The company employs around 163–165 permanent staff as of June 2025, which shows a stable operational structure.
IPO Objectives
The primary objectives of the IPO are:
- Setting up two new manufacturing units in the nutraceutical and veterinary segments (₹34.19 crore).
- Purchase of new machinery to enhance production capacity.
- General corporate purposes to support future growth and operational efficiency.
Conclusion
Overall, Influx Healthtech Limited’s IPO offers investors an opportunity to participate in the growth of a rapidly expanding CDMO in the health and wellness sector. With a strong product portfolio, established client relationships and ambitious expansion plans, the company is well-positioned for future growth. However, as with all SME IPOs, investors should carefully review the company’s fundamentals, market conditions and risk factors before investing.
Influx Healthtech Limited IPO Financial Information
Latest Revenue
104.99
₹ Crore
Profit After Tax
13.37
₹ Crore
Net Worth
36.15
₹ Crore
Total Borrowing
0.22
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 70.3 | 104.99 | 13.37 | 36.15 | 0.22 | ||||
| 31 Mar 2024 | 41.1 | 100.1 | 11 | 22.87 | 0.32 | ||||
| 31 Mar 2023 | 28.3 | 76.07 | 7.2 | 11.65 | 0.8 | ||||
| Amount in ₹ Crore | |||||||||
Influx Healthtech Limited Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 36.98% |
| ROCE | 49.17% |
| Debt/Equity | 0.01 |
| RoNW | 36.98% |
| PAT Margin | 12.75 |
| Price to Book Value | 7.62 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 7.36 | 5.77 |
| P/E (x) | 13.04 | 16.63 |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Diverse Product Portfolio
Strong Clientele
Well-Equipped Manufacturing Plants
Financial Growth
Regulatory Compliance
Download regulatory filings
Influx Healthtech Limited IPO Timeline
| IPO Open Date | Wed, Jun 18, 2025 |
| IPO Close Date | Fri, Jun 20, 2025 |
| Tentative Allotment | Mon, Jun 23, 2025 |
| Initiation of Refunds | Tue, Jun 24, 2025 |
| Credit of Shares to Demat | Tue, Jun 24, 2025 |
| Tentative Listing Date | Wed, Jun 25, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on June 20, 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1200 | ₹1,15,200 |
| Retail (Max) | 1 | 1200 | ₹1,15,200 |
| HNI (Min) | 2 | 2,400 | ₹2,30,400 |